Related Experiment Video

Updated: Feb 13, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer

Abbie E Fearon1, Edward P Carter1, Natasha S Clayton1

  • 1Centre for Tumour Biology, Barts Cancer Institute-a CRUK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UK.

Cell Reports
|March 1, 2018
PubMed

Insights

Downregulation of PHLDA1 drives drug resistance in receptor tyrosine kinase (RTK)-driven cancers. Reactivating PHLDA1 can re-sensitize resistant cancer cells to targeted therapies, offering a new strategy for precision medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Drug resistance to receptor tyrosine kinase (RTK) inhibitors is a major hurdle in precision cancer medicine.
  • Understanding the mechanisms of resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To investigate the role of PHLDA1 in the development and maintenance of drug resistance in RTK-driven cancers.
  • To explore PHLDA1 as a potential biomarker and therapeutic target for overcoming drug resistance.

Main Methods:

  • Utilized fibroblast growth factor receptor (FGFR) inhibition in endometrial cancer cells to study resistance mechanisms.
  • Investigated PHLDA1 expression in response to RTK-targeted therapy in various cancer types (endometrial, breast, renal).
  • Performed PHLDA1 knockdown and induction experiments to assess its impact on drug sensitivity.

Main Results:

  • PHLDA1 downregulation was identified as a critical factor in acquiring and maintaining drug resistance.
  • An Akt-driven compensatory mechanism leading to PHLDA1 downregulation was observed.
  • PHLDA1 downregulation was clinically relevant, occurring in patients treated with RTK inhibitors and trastuzumab.
  • PHLDA1 knockdown conferred de novo resistance, while PHLDA1 induction re-sensitized cells to therapy.

Conclusions:

  • PHLDA1 plays a pivotal role in mediating drug resistance in RTK-driven cancers.
  • PHLDA1 is a potential biomarker for predicting drug response.
  • Reactivation of PHLDA1 presents a promising therapeutic strategy to overcome targeted therapy resistance.
Keywords:
AktFGFcancerdrug resistancetargeted therapytyrosine kinase inhibitor

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.0K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
111.5K
Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
8.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.8K